A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
NCT ID: NCT04459507
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
276 participants
OBSERVATIONAL
2021-03-22
2025-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ocular Complications of Mpox in the Democratic Republic Congo
NCT06579885
Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)
NCT07055867
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
NCT07337564
Uniform Multidrug Therapy Regimen for Leprosy Patients
NCT00669643
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
NCT03429595
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants With Palmoplantar pustulosis (PPP)
Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
No intervention
No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has previously been prescribed treatment for PPP
* A decision has been made by the treating physician and the participant to commence treatment with a systemic PPP therapy, having been deemed to have an inadequate response to previous therapy (New users are defined as those participants to commence treatment on baseline visit date. Existing users are defined as those who commenced treatment prior to the baseline visit since 01 November 2019.)
* Must sign a participation agreement/informed consent form allowing data collection and source data verification in accordance with local requirements
Exclusion Criteria
* Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the start of the study or the first data collection time point
* Participation in an investigational study
* Participation in another observational study for guselkumab (including a post marketing surveillance study)
* If the only treatment they have received for PPP has been antibiotics
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Pharmaceutical K.K.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Pharmaceutical K.K., Japan Clinical Trial
Role: STUDY_DIRECTOR
Janssen Pharmaceutical K.K.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akita University Hospital
Akita, , Japan
Juntendo University Hospital
Bunkyō City, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Fukushima Medical University Hospital
Fukushima, , Japan
Hamamatsu University Hospital
Hamamatsu, , Japan
Kansai Medical University Hospital
Hirakata, , Japan
Hiroshima City Asa Citizens Hospital
Hiroshima, , Japan
Seiwakai Hiroshima Clinic
Hiroshima, , Japan
JR Sapporo Hospital
Hokkaido, , Japan
Kita-harima Medical Center
Hyōgo, , Japan
Teikyo University Hospital
Itabashi Ku, , Japan
Okayama Saiseikai General Hospital
Kita-ku, , Japan
Chikamori Hospital
Kochi, , Japan
Kochi Medical School Hospital
Kochi, , Japan
Yamanashi Prefectural Central Hospital
Kofu, , Japan
Kurashiki Medical Center
Kurashiki-shi, , Japan
Kurume University Hospital
Kurume, , Japan
Kuwana City Medical Center
Kuwana, , Japan
Kyoto University Hospital
Kyoto, , Japan
National Hospital Organization Kyoto Medical Center
Kyoto, , Japan
Shinshu University Hospital
Matsumoto, , Japan
Toho University Medical Center, Ohashi Hospital
Meguro-ku, , Japan
Nagoya City University Hospital
Nagoya, , Japan
The Hospital of Hyogo College of Medicine
Nishinomiya, , Japan
Okayama University Hospital
Okayama, , Japan
Oita University Hospital
Ōita, , Japan
Kindai University Hospital
Ōsaka-sayama, , Japan
Shiga University of Medical Science Hospital
Ōtsu, , Japan
Hokkaido University Hospital
Sapporo, , Japan
Sasebo Chuo Hospital
Sasebo, , Japan
Tohoku University Hospital
Sendai, , Japan
Keio University Hospital
Shinjuku-ku, , Japan
Takamatsu Red Cross Hospital
Takamatsu, , Japan
St. Luke's International Hospital
Tokyo, , Japan
Tokyo Medical University Hospital
Tokyo, , Japan
Tokyo Medical University Hachioji Medical Center
Tokyo, , Japan
Fujita Health University Hospital
Toyoake, , Japan
Ehime University Hospital
Tōon, , Japan
Yokosuka Kyosai Hospital
Yokosuka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNTO1959PAP4001
Identifier Type: OTHER
Identifier Source: secondary_id
CR108811
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.